Success Metrics

Clinical Success Rate
37.5%

Based on 3 completed trials

Completion Rate
38%(3/8)
Active Trials
12(50%)
Results Posted
167%(5 trials)
Terminated
5(21%)

Phase Distribution

Ph phase_1
4
17%
Ph phase_2
3
13%
Ph not_applicable
10
42%
Ph phase_3
1
4%

Phase Distribution

4

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution18 total trials
Phase 1Safety & dosage
4(22.2%)
Phase 2Efficacy & side effects
3(16.7%)
Phase 3Large-scale testing
1(5.6%)
N/ANon-phased studies
10(55.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

3 of 9 finished

Non-Completion Rate

66.7%

6 ended early

Currently Active

12

trials recruiting

Total Trials

24

all time

Status Distribution
Active(13)
Completed(3)
Terminated(6)
Other(2)

Detailed Status

Recruiting9
Terminated5
Active, not recruiting3
Completed3
unknown2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
24
Active
12
Success Rate
37.5%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (22.2%)
Phase 23 (16.7%)
Phase 31 (5.6%)
N/A10 (55.6%)

Trials by Status

unknown28%
withdrawn14%
not_yet_recruiting14%
recruiting938%
active_not_recruiting313%
completed313%
terminated521%

Recent Activity

Clinical Trials (24)

Showing 20 of 24 trialsScroll for more
NCT03181256

Early Detection of Lung Cancer

Active Not Recruiting
NCT06224673Phase 2

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Not Yet Recruiting
NCT04424030

International Consortium for Multimodality Phenotyping in Adults With Non-compaction

Active Not Recruiting
NCT07416825Not Applicable

Inter-Observer Delineation Differences in Esophageal Cancer GTV on MR, CT, and PET/CT Protokol šečerov Ermenc 28dec19

Completed
NCT06470282Phase 1

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

Recruiting
NCT06906562Phase 2

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

Recruiting
NCT04504331Phase 1

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Terminated
NCT02361320Not Applicable

Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer

Recruiting
NCT06600906

Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer

Recruiting
NCT05799144Phase 2

pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

Recruiting
NCT04609592Phase 1

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Recruiting
NCT03909477

Longitudinal Study of Xenon-129 MRI Imaging Effects of Cannabis Smoking

Recruiting
NCT04616313

Novel Pulmonary Imaging of Lung Structure and Function in E-cigarette Smokers

Recruiting
NCT04584671

Lung Structure-Function In Survivors of Mild and Severe COVID-19 Infection

Active Not Recruiting
NCT06557512Not Applicable

Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma

Recruiting
NCT01706705Not Applicable

Magnetic Resonance Imaging (MRI) Brachytherapy Applicator Study

Completed
NCT03109262Not Applicable

Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors

Completed
NCT02177773Phase 1

GA-68 DOTA-TOC of Somatostatin Positive Malignancies

Terminated
NCT03089346Not Applicable

Assessment of Bronchial Thickness Using MRI in Asthma

Unknown
NCT01188486Not Applicable

Pulmonary Interstitial Lymphography in Early Stage Lung Cancer

Terminated

Drug Details

Intervention Type
PROCEDURE
Total Trials
24